Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig (SAR443765) Phase 1 in Healthy Adults and Asthma
NCT05366764Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing SAR443765 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events (AEs) /TEAEs at Day 71. Started Jun 2022; status: completed.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05366764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366764.